 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...345678910111213...3839» |
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data. (Pubmed Central) - Nov 24, 2022
Our findings show differences between drugs and can aid treatment decisions alongside real-world safety data. However, data are likely skewed by trial selection criteria and varying number of trials per drug and highlight the need for robust postmarketing pharmacovigilance.
- ||| Journal, Adverse events, Adverse drug reaction: Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase). (Pubmed Central) - Nov 20, 2022
However, data are likely skewed by trial selection criteria and varying number of trials per drug and highlight the need for robust postmarketing pharmacovigilance. We identified possible associations with some adverse fetal and neonatal outcomes, suggesting that vigilance is required when prescribing certain biologics during pregnancy.
- | Retrospective data, Journal: Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance. (Pubmed Central) - Nov 18, 2022
No special safety signal was identified regarding the occurrence of CMs after exposure to abatacept (n = 64), anakinra (n = 20), belimumab (n = 93), ixekizumab (n = 29), rituximab (n = 57), secukinumab (n = 128), tocilizumab (n = 124) and ustekinumab (n = 215). Regarding observed CCAs in the vedolizumab group (n = 113), no firm conclusions can be made based on available information.
- | Journal: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (Pubmed Central) - Nov 16, 2022
Regarding observed CCAs in the vedolizumab group (n = 113), no firm conclusions can be made based on available information. These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Therapy of PsO in Special Subsets of Patients. (Pubmed Central) - Nov 16, 2022
Furthermore, pregnancy and lactation represent a major contraindication to several systemic agents, and only a few studies exist providing the safety of certain drugs during these periods of life of a woman, such as certolizumab pegol. In this paper, we discuss systemic therapeutic strategies, including conventional and biological therapies, in a special subset of patients affected with moderate-to-severe psoriasis focusing on elderly patients and on female patients in fertile age, pregnancy, and lactation.
- || Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Review, Journal: Infection risk in psoriatic patients receiving tumor necrosis factor inhibitors: A 20-year systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Nov 16, 2022
In conclusion, evidence to date suggests an increased overall infection risk that is generally tolerable in patients with psoriatic diseases receiving TNFis. There are no increased risks of serious infections, upper respiratory infections, or nasopharyngitis.
- || Review, Journal: Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. (Pubmed Central) - Nov 15, 2022
There are no increased risks of serious infections, upper respiratory infections, or nasopharyngitis. The results of this SLR, together with one SLR on safety of DMARD and one on glucocorticoids, informed the taskforce of the 2022 update of the EULAR recommendations for pharmacological management of RA.
- | Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Journal: Certolizumab Pegol in the Treatment of Severe Hidradenitis Suppurativa After Adalimumab Failure: A Real-Life Experience. (Pubmed Central) - Nov 5, 2022
The results of this SLR, together with one SLR on safety of DMARD and one on glucocorticoids, informed the taskforce of the 2022 update of the EULAR recommendations for pharmacological management of RA. Certolizumab pegol is a promising treatment option for severe, recalcitrant HS patients who are unresponsive to adalimumab.
- ||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Journal, Adverse events: Potential Cerebrovascular Accident Signal for Risankizumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS). (Pubmed Central) - Nov 3, 2022
This study detected a previously unreported signal of disproportionate CVA reporting with the real-world use of risankizumab. Further long-term observational data will be necessary to better characterize this unconfirmed potential safety signal.
- || Retrospective data, Review, Journal: Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Oct 28, 2022
No significant differences in DAE were detected between bDMARDs. In conclusion, anti-tumor necrosis factor agents (adalimumab, infliximab, and etanercept) may be preferred for treating psoriatic arthritis for their superiority in preventing radiographic progression.
- || Stelara (ustekinumab) / J&J
Clinical, Journal: Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis. (Pubmed Central) - Oct 26, 2022
In conclusion, anti-tumor necrosis factor agents (adalimumab, infliximab, and etanercept) may be preferred for treating psoriatic arthritis for their superiority in preventing radiographic progression. Other biologics and apremilast were associated with a 1.4- to 3-times higher risk of hospitalization for serious infections in PsO/PsA patients when compared to ustekinumab; this finding should be considered in the safety profile of these therapies when selecting appropriate treatment regimens in patients with PsO/PsA.
- INFLAMMATORY BOWEL DISEASES ARE ASSOCIATED WITH AN INCREASED RISK OF ALCOHOL-ASSOCIATED HEPATITIS IN PATIENTS WITH ALCOHOL USE DISORDER () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1612;
Additionally, the association was stronger with more severe phenotypes of IBD. Conversely, the link appears attenuated for patients receiving IBD-directed therapy.
- || Cimzia (certolizumab pegol) / Astellas, UCB
P1 data, Clinical Trial,Phase I, Journal: Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. (Pubmed Central) - Oct 22, 2022
P1
The median duration of response was 9.0 months (range 5.9 to 42.6 months) and median PFS was 7.1 months (95% CI 6.3 to NR). The standard 400 mg dose of certolizumab, added to cisplatin and pemetrexed, is well-tolerated and, as a correlative endpoint, demonstrates potent pharmacodynamic inhibition of peripheral cytokines associated with the paracrine inflammatory loop.
- | Rinvoq (upadacitinib) / AbbVie
Journal: Upadacitinib for Spondyloarthritis; A new treatment option. (Pubmed Central) - Oct 22, 2022
the lack of oral therapy options, and the stigma associated with surgical intervention makes it crucial to offer an unambiguous treatment choice, especially in light of the disease's strong heredity. Thus, Upadacitinib's usage in the treatment of nr-axSpA and its clinical trial is a significant step toward the availability of an internationally-approved medicine for the treatment of nr-axSpA.
- || Review, Journal: Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. (Pubmed Central) - Oct 22, 2022
New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA, while IL-23i failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety.
- || Review, Journal: Tapering biologics in axial spondyloarthritis: A systematic literature review. (Pubmed Central) - Oct 21, 2022
To conclude, published data indicate that a progressive tapering strategy for anti TNF-α therapy is successful among axial SpA in sustained remission. However, further studies with more homogenized tapering strategies are needed in order to ascertain the specific implication of each subset for a better holistic approach.
- | Opdivo (nivolumab) / BMS, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Trial completion date, Trial primary completion date: Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery (clinicaltrials.gov) - Oct 21, 2022
P2, N=60, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
However, further studies with more homogenized tapering strategies are needed in order to ascertain the specific implication of each subset for a better holistic approach. Not yet recruiting --> Recruiting | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- | Journal: Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. (Pubmed Central) - Oct 12, 2022
Switching between b/tsDMARDs was common among ARAD participants with RA, most commonly due to inefficacy or adverse effects. Durability of exposure and reasons for switching varied between b/tsDMARDs.
- || Review, Journal: A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic medications (DMARDs) in-utero. (Pubmed Central) - Oct 12, 2022
Durability of exposure and reasons for switching varied between b/tsDMARDs. Most evidence for a clinically harmful effect was for early administration of the BCG vaccine to infants exposed in utero to TNF inhibitors with high transplacental transfer rates.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Me too! I will definetly try to keep up with their results 😊 Very interesting to consider anti-TNF (although certolizumab differs a bit from other anti-TNF inhibitors). Let's hope it works! (Twitter) - Oct 8, 2022
- | Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Non-Trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. (Pubmed Central) - Oct 4, 2022
In fully adherent patients, higher SDLs are detected in good responders suggesting that interventions to improve SDLs such as encouraging adherence could improve treatment response. 3-month non-trough SDL cut-offs of 7·5mg/l for Adalimumab and 26·0mg/l for Certolizumab may be useful in clinical practice.
- Cimzia (certolizumab pegol) / Astellas, UCB
Efficacy of CERTOLIZUMAB on steroid-dependent ulcerative pyoderma gangrenosum lesions of the lower limbs (poster space) - Oct 3, 2022 - Abstract #JDP2022JDP_771;
- || Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review. (Pubmed Central) - Oct 1, 2022
The targeted literature review, however, highlighted that there remains a paucity of data beyond these trials. Data from comparative studies would further enhance the body of evidence on the effects of CZP in patients with axSpA who develop AAU.
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Reimbursement: Was on remicade for years, back again when cimzia and humira failed. Doubled the dose and shortened the interval because I was basically calling my doctor's office and the insurance Co daily, ensuring that they had everything they needed and see where things were at. (Twitter) - Sep 30, 2022
- || Clinical, Retrospective data, Journal: Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy. (Pubmed Central) - Sep 29, 2022
Data from comparative studies would further enhance the body of evidence on the effects of CZP in patients with axSpA who develop AAU. The authors did not receive support from any organization for this work.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. (Pubmed Central) - Sep 29, 2022
While initial persistence of TNFi treatment was high, a large proportion of the patients discontinued initial TNFi therapy by 3 years, primarily due to loss of efficacy. While further research identifying potential predictors of TNFi discontinuation in axSpA is warranted, access to alternate disease-modifying therapies is needed.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: THERAPIST: Th17 Responses Evaluated in RA Patients on Inhibitors of TNF? (clinicaltrials.gov) - Sep 26, 2022
P=N/A, N=60, Completed, Sponsor: Queen Mary University of London
While further research identifying potential predictors of TNFi discontinuation in axSpA is warranted, access to alternate disease-modifying therapies is needed. Unknown status --> Completed
- |||| Enrollment open, Trial completion date, Trial primary completion date, Immunomodulating: COVER: COVID-19 VaccinE Response in Rheumatology Patients (clinicaltrials.gov) - Sep 21, 2022
P4, N=1000, Recruiting, Sponsor: Jeffrey Curtis
Unknown status --> Completed Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> May 2023
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Trial completion date, Trial termination: RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) - Sep 19, 2022
P4, N=208, Terminated, Sponsor: Mario Negri Institute for Pharmacological Research
Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> May 2023 Trial completion date: Dec 2023 --> Dec 2021 | Recruiting --> Terminated; Slow recrutiment
- | Cimzia (certolizumab pegol) / Astellas, UCB
بدتر شدن نارسایی قلبی و نارسایی قلبی با onset جدید در استفاده از مهارکنندگان TNF از جمله Certolizumab گزارش شده است؛ به دقت مانیتور شود. قبل از مراجعه به داروخانهها حتما با آنها تماس بگیرید @merck #stopanimaltesting (Twitter) - Sep 19, 2022
- Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability (Room 204) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_3573;
TNFi exposure was further categorized into high (i.e. infliximab, adalimumab, golimumab) and low (i.e. certolizumab, etanercept) placental transfer ability. In this large population sample reflecting real-world utilization of TNFi, we were unable to identify a clear risk of serious infections in children exposed during late pregnancy to TNFi with high versus low placental transfer, although the confidence interval around our estimate was wide
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study (Room 121) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_3339;
Our results indicate an enhanced coagulation and fibrinolytic impairment in newly diagnosed RA patients. Effective antirheumatic treatments reduce this hemostatic imbalance, with significantly more pronounced effects of biologic drugs compared to conventional (MTX+glucocorticoids) treatment.
- Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_3284;
Further studies are necessary to examine whether the clinical effectiveness of different DMARDs varies based on seropositivity.Table 1. Patient Characteristics by DMARD GroupscsDMARD = conventional synthetic disease modifying anti-rheumatic drugs; DMARD = disease modifying anti-rheumatic drugs; IL = interleukin; JAK = Janus kinase; TNF = tumor necrosis factor alpha; Figure 1.
- Cimzia (certolizumab pegol) / Astellas, UCB
How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_3103;
Disease activity, in particular entheseal involvement, seems able to compromise every parameter of WA and extra-work activities; it is interesting to note that some drugs seem more efficacious in preserving WA. Worse working outcomes may determine a significant psychological burden in SpA patients and correlate with an impaired QoL.
- Cimzia (certolizumab pegol) / Astellas, UCB
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2859;
P3
In C-OPTIMISE, 11.7% fewer nr-axSpA patients would have been classified as MRI+ at baseline using the newly proposed definition versus the existing definition. Application of the preliminary MRI definition needs to be evaluated in future clinical trials to confirm its translation into fewer false-positive recruited patients
- Orencia (abatacept) / BMS, Cimzia (certolizumab pegol) / Astellas, UCB
Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2819;
A minority of patients may however fail to achieve a secondary response pointing at the requirement of predictors. The recognized correlation between times to achieve remission after initial treatment and flare re-treatment suggests the possible existence of an individual response predisposition maintained across progressive disease stages
- methotrexate / Generic mfg.
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2798;
The overall risk difference between tapering MTX from targeted therapy or not tapering was low. This review may help inform ACR guidelines, and discussions with patients with controlled disease on any of a range of targeted therapies and MTX, who struggle with MTX-related adverse effects and wish to taper it.
- Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2725;
Table 1. Patient Characteristics by serostatuscsDMARD = conventional synthetic disease modifying anti-rheumatic drugs; DMARD = disease modifying anti-rheumatic drugs; IL = interleukin; JAK = Janus kinase; SD = standard deviation; TNF = tumor necrosis factor alpha.Table 2.
- Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Refractory Macular Edema Due to Behçet's Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2505;
CZP was equally effective despite most patients were refractory to ADA.TABLE. main ocular parameters compared in the CZP-treated group vs.
- Cimzia (certolizumab pegol) / Astellas, UCB
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis (Room 204) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2439;
P3
In the majority of pts, CZP treatment resulted in a reduction of objective measures of inflammation, irrespective of improvements in clinical symptoms and measures of disease activity. The use of clinical response measures as clinical trial endpoints may therefore underestimate anti-inflammatory treatment effects
- Reevaluating Clinical Outcomes of Patients on Combination Biologics (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2143;
Further inquiry is required to determine if certain combinations biologics have a safer risk profile than others. Many biologics were not included in study due lack of unique J-code.
- Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2011;
This systematic review provides important new insights into the management of patients with bDMARDs, across the entire spectrum of axSpA.Figure 1. ASAS40 response in placebo-controlled RCTs of IL-17 inhibitors, by axSpA subtype.
- Cimzia (certolizumab pegol) / Astellas, UCB
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2003;
P, P3
ASAS40 response in placebo-controlled RCTs of IL-17 inhibitors, by axSpA subtype. In pts with nr-axSpA and OSI, long-term clinical outcomes achieved after 1 yr were generally sustained at 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI was numerically highest in the MRI+/CRP+ subgroup
- Humira (adalimumab) / Eisai, AbbVie
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1579;
Demographics and clinical characteristics of patients with baseline REM or LDA receiving ETN and other TNFi monotherapy after combination therapy [disease activity maintenance cohort]Figure 1. Proportion of patients maintaining REM or LDA with ETN versus other TNFi monotherapy in the overall population (a), and in subgroup of patients with REM (b) or LDA (c) at baseline [disease activity maintenance cohort]Figure 2.
- Cimzia (certolizumab pegol) / Astellas, UCB
National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1418;
Anterior was the most frequent uveitis pattern (n=61).In 20 patients, besides the presence of refractory uveitis, desire of pregnancy was the reason for CZP initiation.Prior to CZP, patients had received: methotrexate (n=38), sulfasalazine (28), azathioprine (14), cyclosporine (10), leflunomide (3), mycophenolate mofetil (4), and cyclophosphamide (1)...The most used biologic was adalimumab (n=48), followed by infliximab (32), golimumab (15), tocilizumab (5), etanercept (7), rituximab (1), anakinra (1) and secukinumab (1)... CZP seems to be effective and safe in the control of uveitis associated to different IMIDs.Main ocular parameters analyzed in 80 patients with uveitis due to IMID and treated with CZP
- Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1375;
This nationwide population-based study has demonstrated that in the real world rheumatology practice of biologic monotherapy for RA patients, tocilizumab is the treatment of choice, whereas tofacitinib is the next viable option.Table 1. Univariate and multivariate Cox proportional hazards regression analyses of biologic monotherapy treatment of RA patients
- methotrexate / Generic mfg.
Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1159;
Residual confounding may also be present. These findings suggest that disparities are not easily explained by rurality within the VA healthcare system.
- Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1152;
The most common reason was lack of knowledge of vaccine recommendations. This could be due to frequent guideline changes, patient education, and even healthcare provider education.
- Cimzia (certolizumab pegol) / Astellas, UCB
219: nr-axSpA: Out of the Shadows, Into the Light (Exhibit Hall, Theater B) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1013;
Utilize case studies to explore concepts important to patient assessment and nr-axSpA diagnosis in clinical practice. Review the clinical data supporting CIMZIA® (certolizumab pegol) for the treatment of nr-axSpA.Developed & offered by UCB.
- | Journal: Pharmacological Management of Inflammatory Bowel Disease: a Century of Expert Opinions in Cecil Textbook of Medicine. (Pubmed Central) - Sep 14, 2022
The pillars of drug treatment have been 5-aminosalicylates and corticosteroids. Recent pharmacological innovations (immunomodulators and biologicals) constitute an encouraging paradigm shift in the treatment of UC and Crohn disease.